Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › FL › Daytona Beach › NPI 1265493878
Physician

Halifax Pathology Associates PA

Halifax Pathology Associates PA was paid $942K by Medicaid between Jan 2018 and Dec 2024, across 112 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 19% of everything it billed.

33Billing provider infoHALIFAX PATHOLOGY ASSOCIATES PA
DAYTONA BEACH, FL 32114
33aNPI1265493878assigned 03/31/2006
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$942K
24GClaims537,005
24DCodes billed112
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Anatomic Pathology & Clinical Pathology Physician providers in Florida

Rank by total paid#20 of 207
Median peer was paid$39K
This provider vs. median24×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$10K$20K$30K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201824,542$21K
201989,166$115K
202072,080$152K
202175,666$149K
202282,779$173K
2023109,676$212K
2024incomplete83,096$121K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
88305 Level IV - Surgical pathology, gross and microscopic examination 19% 3,329 2,840 $177K
80053 Comprehensive metabolic panel 12% 52,618 31,669 $116K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) 7.1% 8,570 8,092 $67K
84443 Thyroid stimulating hormone (TSH) 5.0% 8,629 7,380 $48K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 4.8% 66,874 37,937 $45K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type 4.4% 25,182 13,131 $42K
82948 3.7% 30,236 7,959 $35K
80048 Basic metabolic panel (calcium, ionized) 3.1% 21,798 11,050 $30K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 2.2% 494 452 $21K
86850 2.0% 7,404 6,319 $19K
84484 1.9% 13,192 9,402 $18K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 1.7% 4,287 3,868 $16K
100 more codes
81001 1.4% 29,046 $14K
84702 1.4% 5,300 $13K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 1.4% 347 $13K
87040 1.4% 6,750 $13K
80074 1.3% 1,166 $13K
86140 1.3% 5,905 $12K
84703 1.2% 17,883 $12K
87081 1.1% 6,442 $10K
82552 1.1% 3,048 $10K
83735 1.1% 18,083 $10K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 4,285 $9K
87807 <1% 5,606 $9K
88307 <1% 175 $9K
84146 <1% 2,953 $9K
87210 <1% 2,883 $9K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 6,415 $8K
86900 <1% 10,400 $8K
85730 <1% 10,579 $6K
83605 <1% 6,469 $6K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 8,976 $6K
87086 Culture, bacterial; quantitative colony count, urine <1% 9,553 $6K
82140 <1% 1,526 $6K
83690 <1% 11,033 $6K
88312 <1% 559 $5K
87077 <1% 3,666 $5K
80320 <1% 2,073 $5K
85027 <1% 8,357 $5K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 205 $4K
87186 <1% 4,458 $4K
82550 <1% 7,173 $4K
80202 <1% 2,876 $4K
87641 <1% 1,594 $4K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 40 $3K
85610 <1% 12,958 $3K
80061 Lipid panel <1% 5,055 $3K
84100 <1% 7,427 $3K
86901 <1% 10,586 $3K
86403 <1% 2,152 $3K
87070 <1% 3,223 $3K
83036 Hemoglobin; glycosylated (A1C) <1% 5,665 $3K
82607 <1% 754 $2K
86592 <1% 1,397 $2K
82805 <1% 229 $2K
80329 <1% 633 $2K
85379 <1% 2,760 $2K
87205 <1% 3,583 $2K
87420 <1% 935 $1K
82247 <1% 2,162 $1K
86880 <1% 1,852 $993.50
83880 <1% 2,404 $825.53
82728 <1% 788 $770.41
82565 <1% 1,579 $662.97
85384 <1% 820 $633.28
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 48 $623.81
85652 <1% 2,258 $550.55
80076 <1% 1,010 $537.18
82248 <1% 1,118 $517.40
83615 <1% 1,187 $516.72
84439 <1% 815 $509.37
86762 <1% 390 $500.62
84132 <1% 1,848 $442.21
86920 <1% 62 $389.80
83550 <1% 501 $387.59
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 268 $385.25
83721 <1% 297 $355.94
84295 <1% 864 $328.74
82570 <1% 671 $290.28
83540 <1% 556 $269.98
82746 <1% 185 $256.32
84550 <1% 514 $193.31
87102 <1% 112 $181.13
84156 <1% 517 $175.47
82435 <1% 457 $167.18
82947 <1% 561 $159.15
85018 <1% 835 $158.21
85014 <1% 747 $139.88
85044 <1% 318 $137.54
87449 <1% 153 $137.30
84520 <1% 422 $120.85
82040 <1% 103 $93.93
86923 <1% 668 $76.44
87206 <1% 83 $67.42
82010 <1% 130 $53.59
84145 <1% 1,424 $52.60
80164 <1% 22 $46.67
85007 <1% 222 $46.49
87116 <1% 25 $41.71
82077 <1% 1,260 $38.22
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 87 $37.92
84157 <1% 99 $26.14
83010 <1% 13 $21.71
85660 <1% 15 $10.95
86038 <1% 13 $10.10
87147 <1% 14 $7.03
84112 <1% 13 $6.39
86431 <1% 15 $5.01
86430 <1% 16 $5.01
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 0% 77 $0.00
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 0% 581 $0.00
87493 0% 12 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSHEHI, LORA (PRESIDENT)